Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Ceftobiprole Medocaril
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Advanz Pharma
Deal Size : $846.0 million
Deal Type : Acquisition
Nordic Capital Acquires Advanz Pharma for $846 Million
Details : Ceftobiprole medocaril, Zevtera, is a novel cephalosporin antibiotic indicated for the treatment of serious bacterial infections in hospitalised patients.
Brand Name : Zevtera
Molecule Type : Small molecule
Upfront Cash : Undisclosed
June 01, 2021
Lead Product(s) : Ceftobiprole Medocaril
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Advanz Pharma
Deal Size : $846.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?
Reset All
